Gemmer Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Gemmer Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-79	Closed	-$9K	–	1486
2019 Q4	$9K	Sell	79 -2	-2%	-$214	﹤0.01%	714
2019 Q3	$8K	Buy	81 +4	+5%	+$451	﹤0.01%	783
2019 Q2	$10K	Sell	77 -10	-11%	-$1.29K	﹤0.01%	680
2019 Q1	$12K	Hold	87	–	–	﹤0.01%	624
2018 Q4	$8K	Hold	87	–	–	﹤0.01%	736
2018 Q3	$12K	Sell	87 -2	-2%	-$251	﹤0.01%	630
2018 Q2	$11K	Hold	89	–	–	﹤0.01%	677
2018 Q1	$10K	Sell	89 -5	-5%	-$598	﹤0.01%	709
2017 Q4	$11K	Sell	94 -44	-32%	-$5.36K	﹤0.01%	681
2017 Q3	$19K	Sell	138 -9	-6%	-$1.22K	0.01%	406
2017 Q2	$18K	Buy	147 +16	+12%	+$1.86K	0.01%	414
2017 Q1	$16K	Hold	131	–	–	0.01%	448
2016 Q4	$16K	Buy	131 +24	+22%	+$2.94K	0.01%	427
2016 Q3	$13K	Buy	107 +9	+9%	+$1.16K	0.01%	497
2016 Q2	$11K	Hold	98	–	–	0.01%	532
2016 Q1	$13K	Hold	98	–	–	0.01%	462
2015 Q4	$19K	Hold	98	–	–	0.01%	319
2015 Q3	$15K	Hold	98	–	–	0.01%	413
2015 Q2	$18K	Hold	98	–	–	0.01%	355
2015 Q1	$17K	Hold	98	–	–	0.01%	397
2014 Q4	$18K	Hold	98	–	–	0.01%	354
2014 Q3	$16K	Hold	98	–	–	0.01%	387
2014 Q2	$15K	Hold	98	–	–	0.01%	422
2014 Q1	$14K	Buy	+98	New	+$15.6K	0.01%	441

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Gemmer Asset Management's ALXN Position: Q1 2020 in Review

Gemmer Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2020, closing a stake of 79 shares — an estimated $9K sold.

Gemmer Asset Management first reported a position in ALXN in Q1 2014 and held it in 24 quarters. The position peaked at $19K in Q3 2017. 654 funds tracked by Wall St. Rank hold ALXN as of Q1 2020.

Gemmer Asset Management reported no remaining Alexion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Gemmer Asset Management sold 79 Alexion Pharmaceuticals shares in Q1 2020, an estimated $9K.
Gemmer Asset Management first reported a position in Alexion Pharmaceuticals in Q1 2014 and held it in 24 quarters.
Gemmer Asset Management's Alexion Pharmaceuticals position peaked at $19K in Q3 2017.
654 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2020.

Based on Gemmer Asset Management's 13F filing for Q1 2020, filed 1 May 2020.